#187 - Safety of Baricitinib in Patients with Atopic Dermatitis: Results of Pooled Data from Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)
Kerry Doe, MI; Dana Doe, CK; Pat Doe, EY; Robert Goren, MO; Lenny Briscoe, US; Olivia Benson, E
#189 - Rapid and Concurrent Improvements in Signs and Symptoms of Atopic Dermatitis with Baricitinib in Phase 3 Studies
EL Simpson, JP Thyssen, R Bissonnette, B Jia, FP Nunes, M Casillas, AM DeLozier, MJ Rueda, JM Janes, X Zhang, M Gamalo, E Guttman-Yassky, K Reich, T Bieber
#191 - Lebrikizumab, a high affinity IL-13 inhibitor, improves moderate-to-severe atopic dermatitis regardless of patient race: Post hoc analysis from a phase 2b study
A Armstrong, TE Schlesinger, R Gopalan, J Drew, J Weisman, E Guttman-Yassky